Thomas M Atkinson1, Joel Palefsky2, Yuelin Li3, Andrew Webb3, J Michael Berry2, Stephen Goldstone4, Rebecca Levine5, Timothy J Wilkin6, Gary Bucher7, David Cella8, Jack E Burkhalter3. 1. Memorial Sloan Kettering Cancer Center, New York, NY, USA. atkinsot@mskcc.org. 2. University of California-San Francisco, San Francisco, CA, USA. 3. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Laser Surgery Care, New York, NY, USA. 5. Montefiore Medical Center, New York, NY, USA. 6. Weill Cornell Medicine, New York, NY, USA. 7. Anal Dysplasia Clinic Midwest, Chicago, IL, USA. 8. Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
PURPOSE: The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test-retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI). METHODS: ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7-10 days later to complete the A-HRSI and a participant global impression of change (PGIC) item. RESULTS:Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach's α was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16). CONCLUSIONS: The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7-10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial.
RCT Entities:
PURPOSE: The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test-retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI). METHODS: ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7-10 days later to complete the A-HRSI and a participant global impression of change (PGIC) item. RESULTS:Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach's α was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16). CONCLUSIONS: The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7-10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial.
Authors: Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring Journal: Value Health Date: 2011-10-10 Impact factor: 5.725
Authors: Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring Journal: Value Health Date: 2011-10-13 Impact factor: 5.725
Authors: Matthijs L Siegenbeek van Heukelom; Olivier Richel; Pythia T Nieuwkerk; Henry J C De Vries; Jan M Prins Journal: Dis Colon Rectum Date: 2016-01 Impact factor: 4.585
Authors: Meredith S Shiels; Aimée R Kreimer; Anna E Coghill; Teresa M Darragh; Susan S Devesa Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-07-29 Impact factor: 4.254
Authors: Simon Siu-Man Ng; Wing-Wa Leung; Cherry Yee-Ni Wong; Sophie Sok-Fei Hon; Tony Wing-Chung Mak; Dennis Kwok-Yu Ngo; Janet Fung-Yee Lee Journal: World J Gastroenterol Date: 2013-08-07 Impact factor: 5.742
Authors: Rebecca A Nelson; Alexandra M Levine; Leslie Bernstein; David D Smith; Lily L Lai Journal: J Clin Oncol Date: 2013-03-18 Impact factor: 44.544
Authors: Thomas M Atkinson; Kathleen A Lynch; Jacqueline Vera; Nuria Mendoza Olivares; Andrew Webb; Lisa C Diamond; Javier González; Erica I Lubetkin; Gary Bucher; Isabella Rosa-Cunha; J Michael Berry-Lawhorn; Rebecca Levine; David Aboulafia; Jeffrey Schouten; Susan M Holland; David Cella; Joel M Palefsky Journal: J Patient Rep Outcomes Date: 2022-10-11